Name | Title | Contact Details |
---|
Wright and Filippis is a Rochester Hls, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
Catalyst + Talent. Our name combines these ideas. From drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. With over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. Catalent develops. With our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. Catalent delivers. As the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. Catalent supplies. Globally positioned to serve all your manufacturing and commercial packaging needs, we provide integrated solutions to take your product from design, to clinical trial, to plant, and to pharmacy.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.
Kimochi Home is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.